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avoided by heating the spirometer or using a heated 
pneumotachograph. The problem of truncation of the 
spirogram has previously been argued in the literature 
and limits the usefulness of MTT (3). Other time 
domain indices have been shown to be of value in that 
they more readily identify subjects whose results 
deviate from expected normal values (4). I agree with 
the authors view that MTT is unlikely to play a major 
part in the clinical evaluation of lung function in 
children. However, the reasons behind this finding 
should have been more adequately presented and it is 
possible that other time domain indices, such as a 
truncated first moment, could be extremely useful in a 
paediatric population. 
M. R. MILLER 
4 November 1992 
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Reply to the letter from Dr Miller 
We accept that volume measurements may be over- 
estimated by assuming instantaneous cooling to room 
temperature of air in a wedge spirometer, and that 
mean transit time may therefore be underestimated by 
asmuchas 15%. 
However, because children reach the plateau of the 
forced expirogram much earlier than adults (which is 
why many paediatricians use FEV,.,, rather than FEV 
,.,,, many children having completed the manoeuvre 
within 1 s), the prolonged terminal phase of the 
expirogram, which bedevils studies on adults, is 
seldom seen in children, even in asthmatics, and the 
effects of truncation at 95% FVC would therefore be 
much less than in adults. In our study, readings which 
failed to stabilize were discarded; such tracings usually 
lasted for less than 3 s before the child inspired. As our 
analyses were performed manually, we are not in a 
position to reanalyse the tracings following trunca- 
tion, although we agree that this, and the examination 
of other time domain indices, would be an interesting 
exercise. 
Nevertheless, the effects of delayed cooling cannot 
be ignored and we are grateful to Dr Miller for drawing 
our attention to this problem. 
M. HUDSON, T. K. NINAN AND G. RUSSEL 
3 December 1992 
Dear Editor 
The phenomenon of rifampicin-induced dis- 
colouration of body fluids is well recognized, and urine 
discolouration is widely used as a simple method of 
monitoring treatment compliance. We report a case in 
which the red discolouration disappeared temporarily 
in spite of continued and verified patient compliance. 
A 70-year-old non-insulin-dependent man was 
admitted with smear positive pulmonary tuberculosis. 
Sputum culture subsequently grew Mycotacterium 
tuberculosis, sensitive to the standard drugs. He was 
treated as an in-patient with rifampicin 10 mg kg-’ d-‘, 
isoniazid 300 mg daily, and pyrazinamide 25 mg kg-’ 
d-‘. His only other medication was pyridoxine and 
gliclazide. Initially, as expected, his urine turned 
reddish-orange in colour, but after 3 weeks it was 
noticed that his urine colour had returned to normal, 
even though supervised treatment in hospital had 
continued throughout. 
The N-butanol extraction test was employed in 
further investigation of this phenomenon. Urinary 
rifampicin concentrations of greater than 50 ,ug ml-’ 
are usually visible to the naked eye, but the assay 
detects unmetabolized rifampicin in urine and can con- 
veniently be used to identify urinary concentrations 
down to 2.5 pg ml-’ (1). In this patient the level of 
rifampicin detected in the urine by N-butanol extrac- 
tion was unrecordable. Nevertheless, a sample of his 
urine showed considerable bactericidal activity against 
a precultured StaphyIococcus colony, indicating, in the 
absence of any other active antibiotic, the presence of a 
specific antistaphylococcal agent(s). 
After 2 months treatment, the pyrazinamide was 
discontinued. At this point, the reddish-orange dis- 
colouration of his urine returned. A repeat N-butanol 
extraction assay for rifampicin revealed significant 
amounts of the unchanged drug in the urine. 
It is well known that rifampicin and its metabolites 
are chromogens and impart an orange colouration to 
body secretions, including urine (2). The main 
metabolite, desacetylrifampicin, is microbiologically 
active, with bile as the main route of elimination (3). 
Desacetylation of rifampicin most probably takes 
place in the hepatocyte and results in a more polar 
compound, which facilitates its excretion in bile. 
The ability of rifampicin, pyrazinamide and other 
drugs to induce such reactions reliant on cytochrome 
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P450 and other hepatic enzymes is well recognized. 
Concomitant administration of these drugs reduces 
the effectiveness of other compounds which undergo 
hepatic metabolism due to rapid breakdown. In 
this case it appears likely that rifampicin- and 
pyrazinamide-induced enzyme hyperactivity caused 
excessive metabolism of rifampicin to its more polar 
derivative, desacetylrifampicin, for elimination pri- 
marily in bile, such that the negligible amounts of 
rifampicin and desacetylrifampicin excreted in urine 
were insufficient to turn the urine red or to be detect- 
able by N-butanol assay. Following the withdrawal 
of pyrazinamide, however, the degree of hepatic 
enzyme induction was reduced so the unmetabolized 
rifampicin was excreted in sufficient quantity to dis- 
colour the urine. It is unlikely that malabsorption 
or dietary influences caused the changes in urine 
colour, in view of the presence in urine of micro- 
biologically active compounds throughout the 
duration of treatment. 
This case shows clearly that non-compliance and 
malabsorption are not the only causes of non- 
discolouration of body fluids by rifampicin. 
J.R.MoRGAN,K. W.CLARKEANDS.G.BREAR 
Acute Medical Unit 
North Manchester General Hospital 
Delaunay’s Road 
Crumpsall 
Manchester M8 6RB, U.K. 
27 October 1992 
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Dear Editor 
Hypothalamo-pituitary-adrenal axis suppression in 
asthmatics 
Brown et al. are to be congratulated on their 
two papers on hypothalamo-pituitary-adrenal axis 
suppression in asthmatics. Are their recommendations 
for screening for adrenal suppression based on a wide 
experience of clinical hypo-adrenal crises in their 
patients? 
A.G. LEITCH 
19 November 1991 
Reply to the letter from Dr Leitch 
We thank Dr Leitch for his appreciation of our 
work. Our recommendation that screen tests of 
hypothalamo-pituitary-adrenal axis function should 
be performed in asthmatics taking greater than or 
equal to 1500 fig inhaled steroid daily is based on our 
finding that 20% of our patients taking these doses had 
adrenal suppression. These patients were studied 
whilst in a stable state and the opportunity to examine 
them for evidence of adrenal crisis during acute illness 
has not arisen. 
As far as we are aware, there are no published 
reports of adrenal crisis as a consequence of with- 
drawal of inhaled steroid therapy. Some might 
therefore question the value of detecting biochemical 
evidence of adrenal suppression. We consider it 
important for the following reasons: 
1. HPA suppression is the most widely used marker of 
systemic steroid effect. Patients with HPA suppression 
are likely to be at greater risk of other systemic 
steroid effects. Screening tests allow these patients to 
be identified. 
2. Death from adrenal failure has occurred following 
substitution of inhaled for long-term oral steroid 
therapy (1). We do not think that the adrenal sup- 
pression induced in some patients by high dose inhaled 
steroids differs from that induced by oral or injected 
steroids. If steroid cards are considered necessary 
for patients taking these drugs via the latter routes, 
cards should also be given to patients whose pharma- 
cokinetic handling of high dose inhaled steroids is such 
that they are receiving ‘systemic’ steroid therapy. 
P. BROWN,A.P. GREENINGANDG. K. CROMPTON 
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